This is a working overview of melanocortin receptors, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-28 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
[RO−P(O)2−O−P(O)2−O−PO3]4− + H2O → [RO−P(O)2−O−PO3]3− + [HPO4]2− + H+ [RO−P(O)2−O−P(O)2−O−PO3]4− + H2O → [RO−PO3]2− + [HO3P−O−PO3]3− + H+ For ATP hydrolysis that takes place with the physiological concentrations of ATP, ADP, and inorganic phosphate (Pi) within the living cell, the change in Gibbs free energy is given by:
=== Reaction pathways === Diterpenes are commonly synthesized from the precursor molecule geranylgeranyl pyrophosphate (GGPP). GGPP's hydrocarbon backbone can be rearranged into different structures that may be further rearranged or added to in order to create precursors for different families of diterpenoid compounds. This precursor molecule may be synthesized through the mevalonic acid pathway or the deoxyxylulose pathway. These pathways produce isopentenyl pyrophosphate, which can be rearranged into GGPP. The cyclization of GGPP and the subsequent reorganizations into different precursors is controlled by a large family of enzymes known as diterpene syntheses (diTPS). To synthesize sugiol a plant must first synthesize GGPP through either of the previously mentioned pathways, (mevalonic acid or the deoxyxylulose pathway), then rearrange GGPP into the molecule mitiradiene. After formation of an intermediate compound abietatriene, a cytochrome P450 enzyme can then attach an oxygen molecule to the intermediate. This produces ferruginol, which can then be modified to sugiol by sugiol synthase. Sugiol may then be formed through the modification of ferruginol according to the following reaction driven by the enzyme sugiol synthase.
The blue mackerel is found in tropical to subtropical waters of the Indian and Pacific Oceans. In the Indo-West Pacific, there is a population in the Red Sea and western Arabian Sea, one in the Northwest Pacific (Japan, China, and Taiwan), and another one in the Southwest Pacific (Australia and New Zealand). Furthermore, the blue mackerel also occur in the eastern Pacific (Hawaii and Revillagigedo Islands, Mexico). It occurs in surface waters down to 300 m (980 ft).
=== Sources === Cleveland Clinic. "LADA Diabetes." Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/lada-diabetes. Accessed 9 Apr. 2026. Diabetes UK. "Latent Autoimmune Diabetes (LADA)." Diabetes UK, https://www.diabetes.org.uk/about-diabetes/other-types-of-diabetes/latent-autoimmune-diabetes. Accessed 9 Apr. 2026. Eisenbarth, George S., ed. (2010). Immunoendocrinology: Scientific and Clinical Aspects. Contemporary Endocrinology. Humana Press. ISBN 978-1-603-27477-7. Flynn, John A.; Michael J. Choi; L. Dwight Wooster, eds. (2013). Oxford American Handbook of Clinical Medicine. Oxford American Handbooks in Medicine. Oxford University Press. ISBN 978-0-195-18849-3. HealthNormal. "Latent Autoimmune Diabetes in Adults." HealthNormal, https://www.healthnormal.com/latent-autoimmune-diabetes-in-adults/. Accessed 9 Apr. 2026. "Latent Autoimmune Diabetes in Adults: Current Status and New Horizons." SN Comprehensive Clinical Medicine, 2025, https://link.springer.com/article/10.1007/s42399-025-02003-1. Accessed 9 Apr. 2026. "Management of Latent Autoimmune Diabetes in Adults." Diabetes, vol. 69, no. 10, 2020, https://diabetesjournals.org/diabetes/article/69/10/2037/16062. Accessed 9 Apr. 2026. Munden, Julie, ed. (2006). Diabetes Mellitus: A Guide to Patient Care. Lippincott Williams & Wilkins. ISBN 978-1-58255-732-8. Haskins, Jacqueline. Kickass Healthy LADA: How to Thrive with Latent Autoimmune Diabetes in Adults. Hachette Go (2023). ISBN 9780306830730.
Sources: en.wikipedia.org
The signature colors for In-N-Out are white, red, and yellow. The white is used for the buildings' exterior walls and the employees' basic uniform. Red is used for the buildings' roofs and the employees' aprons and hats. Yellow is used for the decorative band on the roof and iconic arrow in the logo. However, variations in the color scheme do occur.
Second, "modern awards" are set by the Fair Work Commission. In 2024 there were 150 covering different workplace sectors. These have minimum pay scales depending on employees' experience, qualifications, and skills. For example, the "Legal Services Award 2020" sets minimum weekly rates for "levels 1 to 6" for clerical and administrative staff (but not lawyers), the "Reserve Bank of Australia Award 2016" sets "levels 1 to 5" for annual salaries, and the "Higher Education Industry – Academic Staff – Award 2020" sets a 24 level pay scale with both annual salaries for full-time employees, and comparable minimum hourly rates. These awards are usually far lower than under enterprise bargaining agreements, but are designed to place a minimum floor to prevent unfair competition. The objectives of the FWC under section 134 are improving secure work, gender equality, encouraging bargaining and a competitive economy. Under FWA 2009 section 158 an employer, employee, or trade union covered by the award can apply for a variation of an award. Often, "junior" employees under 21 years old are paid less, and are exempt in this respect from age discrimination laws, based on the theory that it may reduce youth unemployment, even though experience in New Zealand is that paying young people less does not encourage them to find work, and abolishing junior rates had no impact on youth employment.
== See also == Other diamond-like compounds: Boron nitride Abiogenic petroleum origin Nanorobot “Diamonoids” were claimed as an airburst proxy, but may have been a misspelling of diamondoid in a now-retracted paper.
cleavage 1. The physical separation of a dividing parent cell into multiple individual daughter cells. 2. In embryology, the series of mitotic divisions by which a fertilized ovum is divided, without an accompanying overall change in size, into a ball of smaller cells constituting the early embryo.
==== Reaction with lipids ==== Hypochlorous acid reacts with unsaturated bonds in lipids, but not saturated bonds, and the ClO− ion does not participate in this reaction. This reaction occurs by hydrolysis with addition of chlorine to one of the carbons and a hydroxyl to the other. The resulting compound is a chlorohydrin. The polar chlorine disrupts lipid bilayers and could increase permeability. When chlorohydrin formation occurs in lipid bilayers of red blood cells, increased permeability occurs. Disruption could occur if enough chlorohydrin is formed. The addition of preformed chlorohydrin to red blood cells can affect permeability as well. Cholesterol chlorohydrin have also been observed, but do not greatly affect permeability, and it is believed that Cl2 is responsible for this reaction. Hypochlorous acid also reacts with a subclass of glycerophospholipids called plasmalogens, yielding chlorinated fatty aldehydes which are capable of protein modification and may play a role in inflammatory processes such as platelet aggregation and the formation of neutrophil extracellular traps.
Sources: en.wikipedia.org
For example, the pressure needed to drive a viscous fluid up against gravity would contain both that as needed in Poiseuille's law plus that as needed in Bernoulli's equation, such that any point in the flow would have a pressure greater than zero (otherwise no flow would happen). Another example is when blood flows into a narrower constriction, its speed will be greater than in a larger diameter (due to continuity of volumetric flow rate), and its pressure will be lower than in a larger diameter (due to Bernoulli's equation). However, the viscosity of blood will cause additional pressure drop along the direction of flow, which is proportional to length traveled (as per Poiseuille's law). Both effects contribute to the actual pressure drop.
Filament end-tracking protein (Formins, VASP and N-WASP) Filament-nucleator known as the Arp2/3 complex (Actin-related protein-2/3) Filament cross-linkers (e.g., α-actinin, fascin, and fimbrin) Actin monomer-binding proteins profilin and thymosin β4 Filament barbed-end cappers such as Capping Protein and CapG, etc. Filament-severing proteins like gelsolin. Actin depolymerizing proteins such as ADF/cofilin. The actin filament network in non-muscle cells is highly dynamic. The actin filament network is arranged with the barbed-end of each filament attached to the cell's peripheral membrane by means of clamped-filament elongation motors, the above-mentioned "actoclampins", formed from a filament barbed-end and a clamping protein (formins, VASP, Mena, WASP, and N-WASP). The primary substrate for these elongation motors is profilin-actin-ATP complex which is directly transferred to elongating filament ends. The pointed-end of each filament is oriented toward the cell's interior. In the case of lamellipodial growth, the Arp2/3 complex generates a branched network, and in filopodia a parallel array of filaments is formed.
According to the National Drug Intelligence Center, Mexican cartels are the predominant smugglers and wholesale distributors of South American cocaine and Mexico-produced cannabis, methamphetamine, and heroin. The U.S. State Department estimates that 90 percent of cocaine entering the United States is produced in Colombia, followed by Bolivia and Peru, and that the main transit route is through Mexico. Mexican cartels control large swaths of territory, and most of the illegal drugs coming into the U.S., employing land routes, maritime shipments, smuggling tunnels, and other concealment methods. Cartels have waged violent turf battles over control of key smuggling corridors from Matamoros to Tijuana. Cartels operate clandestine laboratories that process precursor chemicals into synthetic drugs. These chemicals are primarily imported from Asia, especially China and India, and are used to manufacture methamphetamine and fentanyl in large quantities. Since the 2010s, fentanyl has become one of the most profitable components of cartel operations due to its low production cost and high potency. Although Mexico accounts for only a small share of worldwide heroin production, it supplies a large share of the heroin distributed in the United States. Since the 2000s, Mexican cartels have profited from marijuana cultivation in remote U.S. forests. A 2018 study found that the reduction in drugs from Colombia contributed to Mexican drug violence.
== Pharmacological modulation == Neutral endopeptidase (NEP) also known as neprilysin is the enzyme that metabolizes natriuretic peptides. Several inhibitors of NEP are currently being developed to treat disorders ranging from hypertension to heart failure. Most of them are dual inhibitors (NEP and ACE). In 2014, PARADIGM-HF study was published in NEJM. This study considered as a landmark study in treatment of heart failure. The study was double blinded; compared LCZ696 versus enalapril in patients with heart failure. The study showed lower all cause mortality, cardiovascular mortality and hospitalization in LCZ696 arm. Omapatrilat (dual inhibitor of NEP and angiotensin-converting enzyme) developed by BMS did not receive FDA approval due to angioedema safety concerns. Other dual inhibitors of NEP with ACE/angiotensin receptor are (in 2003) being developed by pharmaceutical companies.
Several independent evolutionary studies have suggested that Gly, Ala, Asp, Val, Ser, Pro, Glu, Leu, Thr may belong to a group of amino acids that constituted the early genetic code, whereas Cys, Met, Tyr, Trp, His, Phe may belong to a group of amino acids that constituted later additions of the genetic code.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.